Meta-analysis of chemotherapy and dendritic cells with cytokine-induced killer cells in the treatment of non-small-cell lung cancer

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 8, 2015, Pages 14527-14537

  Zheng, Chenhong ^a,c   Yu, Ganjun ^b   Wang, Hui ^d   Tang, Airong ^e   Geng, Peiliang ^c   Zhang, Huiming ^c   Zhu, Zhiquan ^c   Li, Fang ^c   Xie, Xiaohua ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c Department of Chinese PLA General Logistics No 2 Clinic Management Support Bureau   (China)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

^e Department of Surgery   (China)

Author keywords

Chemotherapy; Cytokine induced killer cells; DC CIK; Dendritic cells; Immunotherapy; NSCLC

Indexed keywords

ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CYTOKINE INDUCED KILLER CELL; DENDRITIC CELL; DISEASE CONTROL; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; META ANALYSIS; NON SMALL CELL LUNG CANCER; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS;

EID: 84943637188     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Herbst RS, Heymach JV, Lippman SM, Lung cancer. N Engl J Med 2008; 359: 1367-80.
3. Zheng YW, Li RM, Zhang XW, Ren XB. Current adoptive immunotherapy in non-small cell lung cancer and potential influence of therapy outcome. Cancer Invest 2013; 31: 197-205.
4. Kobayashi K, Hagiwara K. Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC). Target Oncol 2013; 8: 27-33.
5. Hui KM. CIK cells--current status, clinical perspectives and future prospects--the good news. Expert Opin Biol Ther 2012; 12: 659-61.
6. Wang W, Meng M, Zhang Y, Wei C, Xie Y, Jiang L, Wang C, Yang F, Tang W, Jin X, Chen D, Zong J, Hou Z, Li R. Global transcriptome-wide analysis of CIK cells identify distinct roles of IL-2 and IL-15 in acquisition of cytotoxic capacity against tumor. BMC Med Genomics 2014; 7: 49.
7. Pievani A, Borleri G, Pende D, Moretta L, Rambaldi A, Golay J, Introna M. Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood 2011; 118: 3301-10.
8. Schmidt-Wolf IG, Negrin RS, Kiem HP. Blume KG, Weissman IL, Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 1991; 174: 139-49.
9. Joshi PS, Liu JQ, Wang Y, Chang X, Richards J, Assarsson E, Shi FD, Ljunggren HG, Bai XF. Cytokine-induced killer T cells kill immature dendritic cells by TCR-independent and perforin-dependent mechanisms. J Leukoc Biol 2006; 80: 1345-53.
10. Wang X, Yu W, Li H, Yu J, Zhang X, Ren X, Cao S. Can the dual-functional capability of CIK cells be used to improve antitumor effects? Cell Immunol 2014; 287: 18-22.
11. Schmidt-Wolf IG, Finke S, Trojaneck B, Denkena A, Lefterova P, Schwella N, Heuft HG, Prange G, Korte M, Takeya M, Dorbic T, Neubauer A, Wittig B, Huhn D. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer 1999; 81: 1009-16.
12. Mesiano G, Todorovic M, Gammaitoni L, Leuci V, Giraudo Diego L, Carnevale-Schianca F, Fagioli F, Piacibello W, Aglietta M, Sangiolo D. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Expert Opin Biol Ther 2012; 12: 673-84.
13. Schmeel LC, Schmeel FC, Coch C, Schmidt-Wolf IG. Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol 2015; 141: 839-49.
14. Li H, Wang C, Yu J, Cao S, Wei F, Zhang W, Han Y, Ren XB. Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery. Cytotherapy 2009; 11: 1076-1083.
15. Yang L, Ren B, Li H, Yu J, Cao S, Hao X, Ren X. Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients. Cancer Immunol Immunother 2013; 62: 65-73.
16. Zhao M, Li H, Li L, Zhang Y. Effects of a gemcitabine plus platinum regimen combined with a dendritic cell-cytokine induced killer immunotherapy on recurrence and survival rate of non-small cell lung cancer patients. Exp Ther Med 2014; 7: 1403-1407.
17. Zhong R, Teng J, Han B, Zhong H. Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer. Cancer Immunol Immunother 2011; 60: 1497-502.
18. Shi SB, Ma TH, Li CH, Tang XY. Effect of maintenance therapy with dendritic cells: cytokine-induced killer cells in patients with advanced non-small cell lung cancer. Tumori 2012; 98: 314-319.
19. Zhang J, Mao G, Han Y, Yang X, Feng H, Jia L. The clinical effects of DC-CIK cells combined with chemotherapy in the treatment of advanced NSCLC. The Chinese-German Journal of Clinical Oncology 2012; 11: 67-71.
20. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013; 342: 1432-3.
21. Zhang Y, Wang J, Wang Y, Lu XC, Fan H, Liu Y, Zhang Y, Feng KC, Zhang WY, Chen MX, Fu X, Han WD. Autologous CIK cell immunotherapy in patients with renal cell carcinoma after radical nephrectomy. Clin Dev Immunol 2013; 2013: 195691.
22. Li XD, Xu B, Wu J, Ji M, Xu BH, Jiang JT, Wu CP. Review of Chinese clinical trials on CIK cell treatment for malignancies. Clin Transl Oncol 2012; 14: 102-8.
23. Qu HQ, Zhou XS, Zhou XL, Wang J. Effect of DC-CIK cell on the proliferation, apoptosis and differentiation of leukemia cells. Asian Pac J Trop Med 2014; 7: 659-62.
24. Pan Y, Tao Q, Wang H, Xiong S, Zhang R, Chen T, Tao L, Zhai Z. Dendritic cells decreased the concomitant expanded Tregs and Tregs related IL-35 in cytokine-induced killer cells and increased their cytotoxicity against leukemia cells. PLoS One 2014; 9: e93591.
25. Wang YY, Wang YS, Liu T, Yang K, Yang GQ, Liu HC, Wang SS, Yang JL. Efficacy study of CyberKnife stereotactic radiosurgery combined with CIK cell immunotherapy for advanced refractory lung cancer. Exp Ther Med 2013; 5: 453-56.
26. Zhu H, Yang X, Li J, Ren Y, Zhang T, Zhang C, Zhang J, Li J, Pang Y. Immune response, safety and survival and quality of life outcomes for advanced colorectal cancer patients treated with dendritic cell vaccine and cytokine-induced killer cell therapy. Biomed Res Int 2014; 2014: 603871.
27. Shi SB, Tang XY, Tian J, Chang CX, Li P, Qi JL. Efficacy of erlotinib plus dendritic cells and cytokine-induced killer cells in maintenance therapy of advanced non-small cell lung cancer. J Immunother 2014; 37: 250-5.
28. Thanendrarajan S, Kim YSchmidt-Wolf I. New adoptive immunotherapy strategies for solid tumours with CIK cells. Expert Opin Biol Ther 2012; 12: 565-72.